CN107462729B - A kind of Apolipoprotein A1 detection kit and detection method - Google Patents
A kind of Apolipoprotein A1 detection kit and detection method Download PDFInfo
- Publication number
- CN107462729B CN107462729B CN201710678429.XA CN201710678429A CN107462729B CN 107462729 B CN107462729 B CN 107462729B CN 201710678429 A CN201710678429 A CN 201710678429A CN 107462729 B CN107462729 B CN 107462729B
- Authority
- CN
- China
- Prior art keywords
- reagent
- buffer solution
- apolipoprotein
- polyethylene glycol
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000005666 Apolipoprotein A-I Human genes 0.000 title claims abstract description 66
- 108010059886 Apolipoprotein A-I Proteins 0.000 title claims abstract description 66
- 238000001514 detection method Methods 0.000 title claims abstract description 55
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 84
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims abstract description 17
- 239000001639 calcium acetate Substances 0.000 claims abstract description 17
- 235000011092 calcium acetate Nutrition 0.000 claims abstract description 17
- 229960005147 calcium acetate Drugs 0.000 claims abstract description 17
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 8
- 238000012360 testing method Methods 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 46
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000007853 buffer solution Substances 0.000 claims description 37
- 239000002202 Polyethylene glycol Substances 0.000 claims description 36
- 229920001223 polyethylene glycol Polymers 0.000 claims description 36
- -1 ethylphenyl Chemical group 0.000 claims description 28
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 239000003755 preservative agent Substances 0.000 claims description 25
- 230000002335 preservative effect Effects 0.000 claims description 25
- 239000011780 sodium chloride Substances 0.000 claims description 23
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 13
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 13
- 239000007983 Tris buffer Substances 0.000 claims description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 10
- 238000002835 absorbance Methods 0.000 claims description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- 229940098773 bovine serum albumin Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 239000001103 potassium chloride Substances 0.000 claims description 9
- 235000011164 potassium chloride Nutrition 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 241001494479 Pecora Species 0.000 claims description 8
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 8
- 239000007993 MOPS buffer Substances 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000008351 acetate buffer Substances 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 3
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 claims description 3
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 229960003742 phenol Drugs 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 2
- 239000004353 Polyethylene glycol 8000 Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 2
- 239000011654 magnesium acetate Substances 0.000 claims description 2
- 235000011285 magnesium acetate Nutrition 0.000 claims description 2
- 229940069446 magnesium acetate Drugs 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- 229940085678 polyethylene glycol 8000 Drugs 0.000 claims description 2
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 claims description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims 1
- 235000019345 sodium thiosulphate Nutrition 0.000 claims 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 description 19
- 238000005259 measurement Methods 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 238000001914 filtration Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/82—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/82—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity
- G01N2021/825—Agglutination
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides a kind of Apolipoprotein A1 detection kit, it includes reagent R1 and reagent R2, wherein include Nonidet P40 0.8-51g/L in reagent R1, includes Nonidet P40 0.8-51g/L, magnesium salts 0.01-15.5g/L, calcium acetate 0.01-20g/L and antibody in reagent R2.Kit antibody performance of the invention is good, reproducible, reagent testing result is accurate, can satisfy requirement.
Description
Technical Field
The invention relates to the field of medical immunization in-vitro diagnosis, and in particular relates to an apolipoprotein A1 detection kit and a detection method.
Background
Turbidimetry is widely used in clinical testing. Immunoturbidimetry is now the most commonly used.
Most of the early immunoassay techniques analyze the presence or absence and content of specific proteins in a sample to be detected by observing the formation of precipitates, agglutination and hemolysis and measuring light scattering caused by aggregates, such as immunodiffusion, immunoelectrophoresis, direct and brief hemagglutination, passive hemagglutination, complement fixation experiments, etc., and these detection methods have the advantages of low cost, easy judgment of results, and easy technical mastery, and can be widely used for detecting various types of clinical samples. However, the above-mentioned methods tend to be eliminated due to their cumbersome operation, time-consuming and poor sensitivity and accuracy.
Immunoturbidimetry overcomes the above disadvantages and allows the development of automated instruments with precise quantitation in combination with clinical requirements. Therefore, for immunological detection, the immunoturbidimetry has the specificity of combining immunological antigen and antibody, has the characteristic of biochemical reaction, can detect a trace amount of substance to be detected in body fluid, particularly blood, on an automatic biochemical instrument, and is a practical clinical test technology with application prospect.
Immunoturbidimetry (Turbidimetric inhibition assay) is an antigen-antibody binding kinetic assay. The basic principle is as follows: when the antigen and antibody react in a special dilution system and in a suitable ratio (generally, an excess amount of antibody is specified), the formed soluble immune complex precipitates from the liquid phase under the action of the aggregation promoter in the dilution system to form microparticles, and turbidity appears in the reaction solution. When the antibody concentration is fixed, the amount of the immunocomplex formed increases with the increase in the amount of the antigen in the sample, and the turbidity of the reaction solution also increases. The content of the antigen in the sample can be calculated by measuring the turbidity of the reaction solution and comparing with a series of standard products.
Various detection instruments developed and developed based on the basic principle of immunoturbidimetry have been widely used in many aspects of clinical examination, which is the basic working principle of optical methods and immunological methods of blood coagulators; the method is a determination principle of apolipoprotein, hapten and other proteins in full-automatic biochemical determination; meanwhile, the method can also be applied to microorganism detection. By accurately quantifying a variety of substances, there is great clinical significance in the diagnosis, treatment and prognosis evaluation of many diseases.
The clinical commonly used immunoturbidimetry can directly analyze samples in batches on a full-automatic biochemical analyzer due to small sample consumption, and is simple to operate, but the currently established reagents and methods have some defects and shortcomings, which are mainly shown in that:
the antibody is easy to generate flocculent or flaky precipitation in the preservation process, so that the performance of the antibody is poor, the repeatability is poor, and the Coefficient of Variation (CV) is increased, the detection result of the reagent is inaccurate, a filtering step is added, the operation is complex, the antibody can be removed by filtering, the detection effect is influenced, a certain influence is caused on a patient, and the use requirement cannot be met.
Disclosure of Invention
In order to solve the problems, the invention discloses an apolipoprotein A1 detection kit and a detection method, and the kit has the advantages of good reagent stability, good uniformity, good detection result accuracy, convenience in operation and convenience in popularization and application.
In order to achieve the purpose, the invention provides the following technical scheme:
the invention provides an apolipoprotein A1 detection kit, which comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises 0.8-51g/L of ethylphenylpolyethylene glycol, and the reagent R2 comprises 0.8-51g/L of ethylphenylpolyethylene glycol, 0.01-15.5g/L of magnesium salt, 0.01-20g/L of calcium acetate and 10-1000mg/L of antibody.
An apolipoprotein A1 detection kit, wherein the ethyl phenyl polyethylene glycol in the reagent R1 is 5-40g/L, preferably 28 g/L; the ethyl phenyl polyethylene glycol in the reagent R2 is 4-42g/L, preferably 28 g/L.
An apolipoprotein A1 detection kit, wherein the magnesium salt is 0.05-10g/L, preferably 6 g/L; the magnesium salt is preferably one or more of magnesium sulfate, magnesium chloride or magnesium acetate.
The detection kit for the apolipoprotein A1 comprises 0.04-16g/L of calcium acetate, and preferably 12g/L of calcium acetate.
Wherein,
the reagent R1 also comprises buffer solution, inorganic salt, preservative and aggregate; preferably, the reagent R1 further comprises buffer solution 20-150mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L and aggregate 1-60 g/L.
The reagent R2 further comprises a buffer solution, an inorganic salt and a preservative, and preferably, the reagent R2 further comprises 20-100mmol/L of the buffer solution, 1-30g/L of the inorganic salt and 0.5-1g/L of the preservative.
An apolipoprotein A1 detection kit further comprises a calibrator, wherein the calibrator adopts multi-point calibration, and the calibrator comprises 20-100mmol/L of buffer solution, 1-30g/L of inorganic salt, 0.1-2g/L of preservative, 0.3-100g/L of glucan, 1-100g/L of trehalose, 1-100g/L of sucrose, 1-100g/L of bovine serum albumin and antigen.
An apolipoprotein A1 detection kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a buffer solution 20-150mmol/L, an inorganic salt 1-30g/L, a preservative 0.5-1g/L, polyethylene glycol 60001-60g/L and ethylphenylpolyethylene glycol 0.8-51g/L, and the reagent R2 comprises a buffer solution 20-100mmol/L, an inorganic salt 1-30g/L, a preservative 0.5-1g/L, an antibody 10-1000mg/L, ethylphenylpolyethylene glycol 0.8-51g/L, magnesium sulfate 0.01-15.5g/L and calcium acetate 0.01-20 g/L;
preferably, the first and second electrodes are formed of a metal,
the reagent R1 comprises a buffer solution 20-150mmol/L, inorganic salt 1-30g/L, a preservative 0.5-1g/L, polyethylene glycol 60001-60g/L and ethyl phenyl polyethylene glycol 5-40g/L, and the reagent R2 comprises a buffer solution 20-100mmol/L, inorganic salt 1-30g/L, a preservative 0.5-1g/L, an antibody 10-1000mg/L, ethyl phenyl polyethylene glycol 4-42g/L, magnesium sulfate 0.05-10g/L and calcium acetate 0.04-16 g/L;
more preferably still, the first and second liquid crystal compositions are,
the reagent R1 comprises a buffer solution 20-150mmol/L, inorganic salt 1-30g/L, a preservative 0.5-1g/L, polyethylene glycol 60001-60g/L and ethyl phenyl polyethylene glycol 28g/L, and the reagent R2 comprises a buffer solution 20-100mmol/L, inorganic salt 1-30g/L, a preservative 0.5-1g/L, an antibody 10-1000mg/L, ethyl phenyl polyethylene glycol 28g/L, magnesium sulfate 6g/L and calcium acetate 12 g/L.
An apolipoprotein A1 detection kit,
preferably, the antibody is a goat anti-human, rabbit anti-human, horse anti-human, mouse anti-human or other animal anti-human antibody;
preferably, the buffer solution is one or more of acetate buffer solution, ammonium chloride buffer solution, phosphate buffer solution, TRIS buffer solution, boric acid buffer solution, glycine buffer solution, CAPSO, MOPS or Hepes buffer solution;
preferably, the inorganic salt is one or two of sodium chloride and potassium chloride;
preferably, the preservative is one or more of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate or ethylmercuric thiosulfate;
preferably, the aggregate is one or more of polyethylene glycol 2000, polyethylene glycol 4000, polyethylene glycol 6000 or polyethylene glycol 8000;
the invention also provides a detection method using the apolipoprotein A1 detection kit, which comprises the following steps:
(1) adding the reagent R1 into a sample to be detected, and uniformly mixing, wherein the volume ratio of the sample to be detected to the reagent R1 is (1-9): 300, incubating at 37 ℃, and reading the absorbance A1 at a certain wavelength;
(2) adding a reagent R2 into the mixed solution obtained in the step (1), and uniformly mixing, wherein the volume ratio of the reagent R2 to the reagent R1 is 1: (1-6) adding, incubating at 37 ℃, and reading the absorbance A2 at a certain wavelength;
(3) obtaining absorbance △ A, wherein the absorbance △ A is A2-A1;
(4) and (3) fitting a standard curve on a full-automatic biochemical analyzer by using the calibrator through a built-in curve fitting mode, and automatically calculating the content of the apolipoprotein A1 in the sample to be detected according to the absorbance.
The aggregate referred to in the present invention is a substance that promotes aggregation of antigen and antibody in a reaction.
The invention provides an apolipoprotein A1 detection kit and a detection method, relating to the following raw material sources:
due to the adoption of the technical scheme, the invention has the beneficial effects that:
the detection kit and the detection method for the apolipoprotein A1 provided by the invention have the advantages of good reagent stability, good uniformity, stable storage of an antibody, no precipitation phenomenon, high antibody titer, good performance, no filtration step, convenience in operation, low cost, accurate detection result, good repeatability and wider universality.
Detailed description of the preferred embodiments
In order to make the technical solutions in the present application better understood, the present invention is further described below with reference to examples, and it is obvious that the described examples are only a part of the examples of the present application, but not all of the examples. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.
Example 1 detection kit for apolipoprotein A1
Reagent R1:
reagent R2:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Sheep anti-human apolipoprotein A1 antibody | 10mg/L |
| Ethyl phenyl polyethylene glycol | 0.8g/L |
| Magnesium sulfate | 0.01g/L |
| Calcium acetate | 0.01g/L |
Calibration products:
ApoA1 antigen was dissolved in standard dilutions (20mmol/L phosphate buffer, 2g/L sodium chloride, 0.1g/L sodium azide, 0.4g/L dextran, 1g/L trehalose, 1g/L sucrose, 2g/L bovine serum albumin), assayed with commercially available control reagents and adjusted to 120mg/L, and stored at-20 ℃. Before use, the apoA1 standard substance is taken out and diluted into different concentrations by standard substance diluent (apoA1 antigen concentration: 0mg/L, 10mg/L, 20mg/L, 50mg/L, 70 mg/L). Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 2 detection kit for apolipoprotein A1
Reagent R1:
| phosphate buffer | 50mmol/L |
| Potassium chloride | 6g/L |
| Phenol and its preparation | 0.7g/L |
| Polyethylene glycol 6000 | 25g/L |
| Ethyl phenyl polyethylene glycol | 51g/L |
Reagent R2:
calibration products:
ApoA1 antigen was dissolved in standard dilutions (50mmol/L glycine buffer, 15g/L sodium chloride, 0.1g/L sodium azide, 50g/L dextran, 25g/L trehalose, 30g/L sucrose, 20g/L bovine serum albumin), assayed with commercially available control reagents and adjusted to 100mg/L, stored at-20 ℃. Before use, the apoA1 standard substance is taken out and diluted into different concentrations by standard substance diluent (apoA1 antigen concentration: 0mg/L, 10mg/L, 30mg/L, 50mg/L, 70 mg/L). Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 3 detection kit for apolipoprotein A1
Reagent R1:
| acetate buffer solution | 90mmol/L |
| Potassium chloride | 20g/L |
| Sodium azide | 0.8g/L |
| Polyethylene glycol 6000 | 50g/L |
| Ethyl phenyl polyethylene glycol | 5g/L |
Reagent R2:
| acetate buffer solution | 90mmol/L |
| Potassium chloride | 20g/L |
| Sodium azide | 0.8g/L |
| Sheep anti-human apolipoprotein A1 antibody | 300mg/L |
| Ethyl phenyl polyethylene glycol | 4g/L |
| Magnesium sulfate | 0.05g/L |
| Calcium acetate | 0.04g/L |
Calibration products:
ApoA1 antigen was dissolved in standard dilutions (70mmol/L TRIS buffer, 20g/L sodium chloride, 1g/L sodium azide, 70g/L dextran, 60g/L trehalose, 60g/L sucrose, 70g/L bovine serum albumin), assayed with commercially available control reagents and adjusted to 200mg/L, stored at-20 ℃. Before use, the apoA1 standard substance is taken out and diluted into different concentrations by standard substance diluent (apoA1 antigen concentration: 2mg/L, 10mg/L, 40mg/L, 60mg/L, 80 mg/L). Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 4 detection kit for apolipoprotein A1
Reagent R1:
| MOPS buffer solution | 150mmol/L |
| Sodium chloride | 25g/L |
| Sodium azide | 1g/L |
| Polyethylene glycol 6000 | 60g/L |
| Ethyl phenyl polyethylene glycol | 40g/L |
Reagent R2:
| MOPS buffer solution | 100mmol/L |
| Sodium chloride | 25g/L |
| Sodium azide | 1g/L |
| Sheep anti-human apolipoprotein A1 antibody | 600mg/L |
| Ethyl phenyl polyethylene glycol | 42g/L |
| Magnesium sulfate | 10g/L |
| Calcium acetate | 16g/L |
Calibration products:
ApoA1 antigen was dissolved in standard dilutions (100mmol/L TRIS buffer, 30g/L sodium chloride, 2g/L sodium azide, 10g/L dextran, 100g/L trehalose, 100g/L sucrose, 100g/L bovine serum albumin), assayed with commercially available control reagents and adjusted to 160mg/L, stored at-20 ℃. Before use, the apoA1 standard substance is taken out and diluted into different concentrations by standard substance diluent (apoA1 antigen concentration: 0mg/L, 20mg/L, 40mg/L, 70mg/L, 100 mg/L). Then filtering and sterilizing by using a filter membrane with the diameter of 0.45 mu m, and storing at the temperature of 2-8 ℃.
Example 5 detection kit for apolipoprotein A1
Reagent R1:
| MOPS buffer solution | 150mmol/L |
| Sodium chloride | 30g/L |
| Sodium azide | 1g/L |
| Polyethylene glycol 6000 | 60g/L |
| Ethyl phenyl polyethylene glycol | 28g/L |
Reagent R2:
| MOPS buffer solution | 100mmol/L |
| Sodium chloride | 30g/L |
| Sodium azide | 1g/L |
| Sheep anti-human apolipoprotein A1 antibody | 1000mg/L |
| Ethyl phenyl polyethylene glycol | 28g/L |
| Magnesium sulfate | 6g/L |
| Calcium acetate | 12g/L |
Calibration products:
ApoA1 antigen was dissolved in standard dilutions (100mmol/L TRIS buffer, 30g/L sodium chloride, 0.5g/L sodium azide, 90g/L dextran, 100g/L trehalose, 100g/L sucrose, 100g/L bovine serum albumin), assayed with commercially available control reagents and adjusted to 120mg/L, and stored at-20 ℃. Before use, the apoA1 standard substance is taken out and diluted into different concentrations by standard substance diluent (apoA1 antigen concentration: 0mg/L, 20mg/L, 50mg/L, 80mg/L, 100 mg/L). Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 6 detection kit for apolipoprotein A1
Reagent R1:
reagent R2:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Sheep anti-human apolipoprotein A1 antibody | 10mg/L |
| Ethyl phenyl polyethylene glycol | 0.8g/L |
| Magnesium sulfate | 0.01g/L |
Calibration products:
ApoA1 antigen was dissolved in standard dilutions (20mmol/L phosphate buffer, 2g/L sodium chloride, 0.1g/L sodium azide, 0.4g/L dextran, 1g/L trehalose, 1g/L sucrose, 2g/L bovine serum albumin), assayed with commercially available control reagents and adjusted to 120mg/L, and stored at-20 ℃. Before use, the apoA1 standard substance is taken out and diluted into different concentrations by standard substance diluent (apoA1 antigen concentration: 0mg/L, 10mg/L, 20mg/L, 50mg/L, 70 mg/L). Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 7 detection kit for apolipoprotein A1
Reagent R1:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Polyethylene glycol 6000 | 1g/L |
| Ethyl phenyl polyethylene glycol | 0.8g/L |
Reagent R2:
calibration products:
ApoA1 antigen was dissolved in standard dilutions (20mmol/L phosphate buffer, 2g/L sodium chloride, 0.1g/L sodium azide, 0.4g/L dextran, 1g/L trehalose, 1g/L sucrose, 2g/L bovine serum albumin), assayed with commercially available control reagents and adjusted to 120mg/L, and stored at-20 ℃. Before use, the apoA1 standard substance is taken out and diluted into different concentrations by standard substance diluent (apoA1 antigen concentration: 0mg/L, 10mg/L, 20mg/L, 50mg/L, 70 mg/L). Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 8 detection kit for Apolipoprotein A1
Reagent R1:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Polyethylene glycol 6000 | 1g/L |
| Tween 20 | 0.8g/L |
Reagent R2:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Sheep anti-human apolipoprotein A1 antibody | 10mg/L |
| Tween 20 | 1g/L |
Calibration products:
ApoA1 antigen was dissolved in standard dilutions (20mmol/L phosphate buffer, 2g/L sodium chloride, 0.1g/L sodium azide, 0.4g/L dextran, 1g/L trehalose, 1g/L sucrose, 2g/L bovine serum albumin), assayed with commercially available control reagents and adjusted to 120mg/L, and stored at-20 ℃. Before use, the apoA1 standard substance is taken out and diluted into different concentrations by standard substance diluent (apoA1 antigen concentration: 0mg/L, 10mg/L, 20mg/L, 50mg/L, 70 mg/L). Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Comparing the detection results of different embodiments, wherein the CV value is STDEV (1-7)/mean value.
1. A sample with an apolipoprotein A1 concentration of 40mg/L was prepared, and the test was repeated 7 times using the kit of example 1, with the test results shown in Table 1.
Table 1: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 1, the apolipoprotein A1 concentrations measured in example 1 in 1 month, 3 months and 12 months are all close to the true values, and the measured variation coefficients (CV values)) are all less than 2%, which indicates that the kit provided by the invention has good repeatability, stable performance and accurate measurement.
2. A sample with an apolipoprotein A1 concentration of 1mg/L was prepared, and the assay was repeated 7 times using the kit of example 2, with the assay results shown in Table 2.
Table 2: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 2, the apolipoprotein A1 concentrations measured in 1 month, 3 months and 12 months in the example 2 are close to the true values, and the measured variation coefficients are less than 2%, which indicates that the kit has good repeatability, stable performance and accurate measurement.
3. A sample with an apolipoprotein A1 concentration of 25mg/L was prepared, and the assay was repeated 7 times using the kit of example 3, with the assay results shown in Table 3.
Table 3: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 3, the apolipoprotein A1 concentrations measured in example 3 in 1 month, 3 months and 12 months are all close to the true values, and the measured variation coefficients are all less than 1%, which indicates that the kit of the invention has good repeatability, stable performance and accurate measurement.
4. A sample with an apolipoprotein A1 concentration of 70mg/L was prepared, and the assay was repeated 7 times using the kit of example 4, with the assay results shown in Table 4.
Table 4: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 4, the apolipoprotein A1 concentrations measured in 1 month, 3 months and 12 months in example 4 are all close to the true values, and the measured variation coefficients are all less than 1%, which indicates that the kit has good repeatability, stable performance and accurate measurement.
5. A sample with an apolipoprotein A1 concentration of 25mg/L was prepared, and the assay was repeated 7 times using the kit of example 5, with the assay results shown in Table 5.
Table 5: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 5, the concentrations of apolipoprotein A1 measured in example 5 at 1 month, 3 months and 12 months are all true values, and the measured variation coefficients are all less than 0.05%, which indicates that the kit of the invention has good repeatability, stable performance and accurate measurement.
6. A sample with an apolipoprotein A1 concentration of 40mg/L was prepared, and the assay was repeated 7 times using the kit of example 6, with the assay results shown in Table 6.
Table 6: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 6, the apolipoprotein A1 concentrations measured in example 6 in 1 month, 3 months and 12 months all deviate from the true values, and the measured variation coefficients are all more than 4%, which indicates that the kit has poor repeatability, unstable performance and inaccurate measurement.
7. A sample with an apolipoprotein A1 concentration of 40mg/L was prepared, and the assay was repeated 7 times using the kit of example 7, with the assay results shown in Table 7.
Table 7: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 7, the apolipoprotein A1 concentrations measured in example 7 in 1 month, 3 months and 12 months all deviate from the true values, and the measured variation coefficients are all more than 4%, which indicates that the kit has poor repeatability, unstable performance and inaccurate measurement.
8. A sample with an apolipoprotein A1 concentration of 40mg/L was prepared, and the assay was repeated 7 times using the kit of example 8, with the assay results shown in Table 8.
Table 8: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 8, the apolipoprotein A1 concentrations measured in example 8 in 1 month, 3 months and 12 months all deviate from the true values, and the measured variation coefficients are all more than 5%, which indicates that the kit has poor repeatability, unstable performance and inaccurate measurement.
It is to be understood that the invention disclosed is not limited to the particular methodology, protocols, and materials described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (16)
1. An apolipoprotein A1 detection kit, which is characterized in that: the kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises 0.8-51g/L of ethylphenyl polyethylene glycol, and the reagent R2 comprises 0.8-51g/L of ethylphenyl polyethylene glycol, 0.01-15.5g/L of magnesium salt, 0.01-20g/L of calcium acetate and 10-1000mg/L of antibody; the reagent R1 also comprises buffer solution, inorganic salt, preservative and aggregate; the reagent R2 also comprises a buffer solution, inorganic salt and a preservative; wherein,
the inorganic salt in the reagent R2 is one or two of sodium chloride and potassium chloride;
the antibody is an animal anti-human apolipoprotein A1 antibody;
the aggregate is one or more of polyethylene glycol 2000, polyethylene glycol 4000, polyethylene glycol 6000 or polyethylene glycol 8000.
2. The apolipoprotein a1 detection kit according to claim 1, wherein: the ethyl phenyl polyethylene glycol in the reagent R1 is 5-40 g/L; the ethyl phenyl polyethylene glycol in the reagent R2 is 4-42 g/L.
3. The apolipoprotein a1 detection kit according to claim 2, wherein: the ethyl phenyl polyethylene glycol in the reagent R1 is 28 g/L; the ethyl phenyl polyethylene glycol in the reagent R2 is 28 g/L.
4. The apolipoprotein a1 detection kit according to claim 1, wherein: the magnesium salt is 0.05-10 g/L; the magnesium salt is one or more of magnesium sulfate, magnesium chloride or magnesium acetate.
5. The apolipoprotein a1 detection kit according to claim 4, wherein: the magnesium salt is 6 g/L.
6. The apolipoprotein a1 detection kit according to claim 1, wherein: the calcium acetate is 0.04-16 g/L.
7. The apolipoprotein a1 detection kit according to claim 6, wherein: the calcium acetate is 12 g/L.
8. The apolipoprotein a1 detection kit according to claim 1, wherein: the reagent R1 also comprises buffer solution 20-150mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L and aggregate 1-60 g/L.
9. The apolipoprotein a1 detection kit according to claim 1, wherein: the reagent R2 further comprises a buffer solution 20-100mmol/L, an inorganic salt 1-30g/L and a preservative 0.5-1g/L, wherein the inorganic salt in the reagent R2 is one or two of sodium chloride and potassium chloride.
10. The apolipoprotein a1 detection kit according to claim 1, wherein: the kit comprises a calibrator, wherein the calibrator is calibrated at multiple points, and the calibrator comprises 20-100mmol/L of buffer solution, 1-30g/L of inorganic salt, 0.1-2g/L of preservative, 0.3-90g/L of glucan, 1-100g/L of trehalose, 1-100g/L of sucrose, 1-100g/L of bovine serum albumin and an antigen, wherein the antigen is apolipoprotein A1 antigen.
11. The apolipoprotein a1 detection kit according to any one of claims 1-10, wherein: the antibody is preferably a sheep anti-human antibody, a rabbit anti-human antibody, a horse anti-human antibody, a mouse anti-human antibody or other animal anti-human antibody;
the buffer solution is preferably one or more of acetate buffer solution, ammonium chloride buffer solution, phosphate buffer solution, TRIS buffer solution, boric acid buffer solution, glycine buffer solution, CAPSO, MOPS or Hepes buffer solution; the inorganic salt is preferably one or two of sodium chloride and potassium chloride;
the preservative is preferably one or more of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate or ethylmercuric sodium thiosulfate.
12. An apolipoprotein A1 detection kit, which is characterized in that: the kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a buffer solution of 20-150mmol/L, inorganic salt of 1-30g/L, a preservative of 0.5-1g/L, polyethylene glycol 60001-60g/L and ethyl phenyl polyethylene glycol of 0.8-51 g/L; the reagent R2 comprises buffer solution 20-100mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L, antibody 10-1000mg/L, ethyl phenyl polyethylene glycol 0.8-51g/L, magnesium sulfate 0.01-15.5g/L, calcium acetate 0.01-20 g/L; wherein,
the inorganic salt in the reagent R2 is one or two of sodium chloride and potassium chloride;
the antibody is an animal anti-human apolipoprotein A1 antibody.
13. The apolipoprotein a1 detection kit according to claim 12, wherein:
the reagent R1 comprises buffer solution 20-150mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L, polyethylene glycol 60001-60g/L, and ethyl phenyl polyethylene glycol 5-40 g/L; the reagent R2 comprises buffer solution 20-100mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L, antibody 10-1000mg/L, ethyl phenyl polyethylene glycol 4-42g/L, magnesium sulfate 0.05-10g/L, calcium acetate 0.04-16 g/L;
14. the apolipoprotein a1 detection kit according to claim 13, wherein:
the reagent R1 comprises buffer solution 20-150mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L, polyethylene glycol 60001-60g/L, and ethyl phenyl polyethylene glycol 28 g/L; the reagent R2 comprises 20-100mmol/L of buffer solution, 1-30g/L of inorganic salt, 0.5-1g/L of preservative, 10-1000mg/L of antibody, 28g/L of ethyl phenyl polyethylene glycol, 6g/L of magnesium sulfate and 12g/L of calcium acetate.
15. The apolipoprotein a1 detection kit according to any one of claims 12-14, wherein: the antibody is a sheep anti-human antibody, a rabbit anti-human antibody, a horse anti-human antibody, a mouse anti-human antibody or other animal anti-human antibody;
the buffer solution is preferably one or more of acetate buffer solution, ammonium chloride buffer solution, phosphate buffer solution, TRIS buffer solution, boric acid buffer solution, glycine buffer solution, CAPSO, MOPS or Hepes buffer solution; the inorganic salt is one or two of sodium chloride and potassium chloride;
the preservative is one or more of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate or ethylmercuric thiosulfate.
16. A method for detection using the apolipoprotein a1 test kit according to any one of claims 1-15 for non-disease diagnostic purposes, comprising the steps of:
(1) adding the reagent R1 into a sample to be detected, and uniformly mixing, wherein the volume ratio of the sample to be detected to the reagent R1 is (1-9): 300, incubating at 37 ℃, and reading the absorbance A1 at a certain wavelength;
(2) adding a reagent R2 into the mixed solution obtained in the step (1), and uniformly mixing, wherein the volume ratio of the reagent R2 to the reagent R1 is 1: (1-6) adding, incubating at 37 ℃, and reading the absorbance A2 at a certain wavelength;
(3) obtaining absorbance △ A, wherein the absorbance △ A is A2-A1;
(4) and (3) fitting a standard curve on a full-automatic biochemical analyzer by using the calibrator through a built-in curve fitting mode, and automatically calculating the content of the apolipoprotein A1 in the sample to be detected according to the absorbance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710678429.XA CN107462729B (en) | 2017-08-10 | 2017-08-10 | A kind of Apolipoprotein A1 detection kit and detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710678429.XA CN107462729B (en) | 2017-08-10 | 2017-08-10 | A kind of Apolipoprotein A1 detection kit and detection method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107462729A CN107462729A (en) | 2017-12-12 |
| CN107462729B true CN107462729B (en) | 2018-11-23 |
Family
ID=60548641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710678429.XA Active CN107462729B (en) | 2017-08-10 | 2017-08-10 | A kind of Apolipoprotein A1 detection kit and detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107462729B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111239405A (en) * | 2020-01-17 | 2020-06-05 | 上海高踪医疗器械科技有限公司 | Apolipoprotein AI detect reagent box |
| CN114540512A (en) * | 2022-03-21 | 2022-05-27 | 成都纳比微特检测技术服务有限公司 | Primer for detecting chicken APOA1 gene and detection method and kit thereof |
| CN115078739B (en) * | 2022-08-22 | 2022-11-22 | 上海执诚生物科技有限公司 | Kit for detecting apolipoprotein A1 and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101025420A (en) * | 2005-09-29 | 2007-08-29 | 华中农业大学 | Avian influenza virus latex agglutination assay kit and its use |
| CN106814193A (en) * | 2016-12-23 | 2017-06-09 | 美康生物科技股份有限公司 | Neutrophil gelatinase-associated lipocalin reagent box for detecting content |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002515260A (en) * | 1998-05-15 | 2002-05-28 | アストラゼネカ アクチボラグ | Scintillation proximity assay for detection of peptidoglycan synthesis |
| GB0622282D0 (en) * | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
-
2017
- 2017-08-10 CN CN201710678429.XA patent/CN107462729B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101025420A (en) * | 2005-09-29 | 2007-08-29 | 华中农业大学 | Avian influenza virus latex agglutination assay kit and its use |
| CN106814193A (en) * | 2016-12-23 | 2017-06-09 | 美康生物科技股份有限公司 | Neutrophil gelatinase-associated lipocalin reagent box for detecting content |
Non-Patent Citations (2)
| Title |
|---|
| 免疫比浊法测定载脂蛋白A-I、载脂蛋白A-II和载脂蛋白B;陈铁珊等;《中日友好医院学报》;19950831;第9卷(第3期);第158-160页 * |
| 应用单克隆抗体的脂蛋白（a）免疫比浊测定;庄一义等;《中华医学检验杂志》;19970930;第20卷(第5期);第281-284页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107462729A (en) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107462731B (en) | A kind of immune globulin A detection reagent box and detection method | |
| US3485587A (en) | Protein indicator | |
| CN107402308A (en) | Immue quantitative detection reagent boxes of IL 6 and preparation method thereof | |
| CN105510604A (en) | Method for improving sensitivity and linearity of latex reagent | |
| CN102636653A (en) | Compounded latex particle-enveloped cystatin C detection kit | |
| CN107462729B (en) | A kind of Apolipoprotein A1 detection kit and detection method | |
| CN114137204B (en) | KL-6 determination kit and preparation and detection method thereof | |
| CN107656069A (en) | Full-range C reactive protein quantitative detecting reagent and method in whole blood | |
| CN107478853B (en) | A kind of apolipoprotein B detection kit and detection method | |
| CN107462730B (en) | A kind of Complement C4 detection kit and detection method | |
| CN107490675B (en) | A kind of Immunoturbidimetric kit and detection method | |
| CN107356764A (en) | A kind of apolipoprotein E detection kit and detection method | |
| CN107490696A (en) | A kind of Retinal-binding protein detection kit and detection method | |
| CN107449919B (en) | A kind of C reactive protein detection kit and detection method | |
| CN107490697B (en) | A kind of kit for testing prealbumin and detection method | |
| CN107490676B (en) | A kind of Complement C_3 detection kit and detection method | |
| CN107478846B (en) | A kind of immunoglobulin G detection reagent box and detection method | |
| CN107478854B (en) | A kind of lipoprotein a detection kit and detection method | |
| CN107422114B (en) | A kind of rheumatoid factor detection reagent box and detection method | |
| CN107478847B (en) | A kind of immune globulin M detection reagent box and detection method | |
| CN107356765B (en) | A kind of immunoglobulin E detection kit and detection method | |
| Alexander et al. | Ion-electrode based immunoassay and antibody-antigen precipitin reaction monitoring | |
| CN107942068A (en) | β2Microglobulin assay kit | |
| JP3513075B2 (en) | Immunoassay and reagent therefor | |
| CN102369441A (en) | Immunoassay method and reagent therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |